Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget’s Disease


  • Mariko Urano-Takaoka
  • Hayakazu Sumida Department of Dermatology, Faculty of Medicine, The University of Tokyo, 113-8655 Tokyo, Japan
  • Takuya Miyagawa Department of Dermatology, Faculty of Medicine, The University of Tokyo, , Japan
  • Kentaro Awaji
  • Kojiro Nagai
  • Jun Omatsu
  • Tomomi Miyake
  • Shinichi Sato



Extramammary Paget’s disease, Cytokeratin 18, tumor marker


Extramammary Paget’s disease (EMPD) is a rare cutaneous adenocarcinoma with unfavourable prognosis once it becomes invasive. A tumour marker that reflects disease progression is required for adequate management of EMPD. Cytokeratin 18 is highly expressed in many types of cancer and its soluble forms are detected by M30 (for caspase-cleaved form) and M65 (for both caspase-cleaved and intact forms) assays. We report here that tumour cells of EMPD in both lesional skin and lymph node metastasis are immunohistochemically positive for CK18, and the baseline serum M30 and M65 levels in patients with metastatic EMPD are significantly higher than those in non-metastatic patients. In addition, serial serum M30 and M65 levels might reflect recurrence of EMPD and response to chemotherapy. These results suggest that serum CK18 levels may be a useful tumour marker for advanced EMPD.


Download data is not yet available.


Tessier-Cloutier B, Asleh-Aburaya K, Shah V, McCluggage WG, Tinker A, Gilks CB. Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. Histopathology 2017; 71: 446-452. DOI:

Ohara K, Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, et al. A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci 2016; 83: 234-239. DOI:

Hashimoto H, Kaku-Ito Y, Furue M, Ito T. The outcome of chemotherapy for metastatic extramammary Paget's disease. J Clin Med 2021; 10: 739. DOI:

Weng YR, Cui Y, Fang JY. Biological functions of cytokeratin 18 in cancer. Mol Cancer Res 2012; 10: 485-493. DOI:

Kramer G, Erdal H, Mertens HJMM, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-1756. DOI:

Menz A, Weitbrecht T, Gorbokon N, Büscheck F, Luebke AM, Kluth M, et al. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Mol Med 2021; 27: 16. DOI:

Shi R, Liu L, Wang F, He Y, Niu Y, Wang C, et al. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer. Oncol Rep 2019; 41: 3015-3026. DOI:

Yin B, Zhang M, Zeng Y, Li Y, Zhang C, Song Y. Downregulation of cytokeratin 18 is associated with paclitaxelresistance and tumor aggressiveness in prostate cancer. Int J Oncol 2016; 49: 848. DOI:

Oshima RG, Baribault H, Caulín C. Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev 1996; 15: 445-471. DOI:

Liegl B, Leibl S, Gogg-Kamerer M, Tessaro B, Horn LC, Moinfar F. Mammary and extramammary Paget's disease: an immunohistochemical study of 83 cases. Histopathology 2007; 50: 439-447. DOI:

Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther 2008; 7: 455-463. DOI:

Tas F, Karabulut S, Yildiz I, Duranyildiz D. Clinical significance of serum M30 and M65 levels in patients with breast cancer. Biomed Pharmacother 2014; 68: 1135-1140. DOI:

Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J Clin Pathol 2000; 53: 742-749. DOI:

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, Van Der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007; 13: 3198-3206. DOI:

Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24. DOI:

Bártek J, Vojtěšek B, Stašková Z, Bártková J, Kerekés Z, Rejther A, et al. A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology. J Pathol 1991; 164: 215-224. DOI:

Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, et al. Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer 2012; 107: 1518-1524. DOI:

Abreu MT, Arnold ET, Chow JYC, Barrett KE. Phosphatidylinositol 3-kinase-dependent pathways oppose fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells: implications for inflammatory diarrheal states. J Biol Chem 2001; 276: 47563-47574. DOI:

Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011; 30: 87. DOI:

Bühler H, Schaller G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 2005; 3: 365-371. DOI:

Umemura H, Yamasaki O, Kaji T, Otsuka M, Asagoe K, Iwatsuki K. Serum carcinoembryonic antigen level as a marker for advanced stage and chemotherapeutic response in extramammary paget's disease. Acta Derm Venereol 2018; 98: 706-707. DOI:



How to Cite

Urano-Takaoka, M., Sumida, H., Miyagawa, T., Awaji, K., Nagai, K., Omatsu, J., Miyake, T., & Sato, S. (2022). Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget’s Disease. Acta Dermato-Venereologica, 102, adv00636.





Most read articles by the same author(s)

1 2 3 > >>